0111 bluebird
BioCentury & Getty Images


bluebird’s split could yield two attractive M&A targets

Jan 12, 2021 | 12:51 AM GMT

bluebird’s decision to focus on rare diseases and spin out its cancer business by year-end could provide the focus both units need to execute on their pipelines and attract potential partners and buyers. 

Nick Leschly, who has led bluebird bio Inc. (NASDAQ:BLUE) as CEO since 2010, will transition to lead the new publicly traded

Read the full 722 word article

How to gain access

Continue reading with a
two-week free trial.